Review of Behçet Disease: Pathogenesis, Clinical Spectrum, and Evolving Therapeutic Strategies

1. Dr. Samatbek Turdaliev

2. Balaraj Omana Naina Bal

    Babu Abhishek

(1. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.

2. Students, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

Abstract

Behçet disease (BD) is a chronic, relapsing, multisystem inflammatory disorder characterized by oral and genital ulcers, ocular inflammation, vascular involvement, and neurological manifestations. Contemporary reviews on Behçet disease aim to integrate genetic susceptibility, immunopathogenesis, clinical heterogeneity, and advances in targeted therapy. This review critically evaluates a representative narrative review on Behçet disease, focusing on its scope, methodological rigor, strengths, limitations, and overall contribution to the field. While the reviewed literature provides a strong overview of immunological mechanisms—particularly the role of innate immunity, Th1/Th17 pathways, and HLA-B51—it lacks transparency in literature selection and insufficiently addresses regional disease burden and implementation challenges in low- and middle-income countries. Emerging biologic therapies, including TNF-α inhibitors and IL-17/IL-1 blockers, are discussed, though critical appraisal of long-term safety and comparative efficacy remains limited. This critique concludes with targeted recommendations to enhance future reviews and identifies priority areas for research in Behçet disease.

Keywords: Behçet disease, vasculitis, HLA-B51, Th17 immunity, biologic therapy, multisystem inflammation, review critique

Introduction

Behçet disease is a complex systemic vasculitis of unknown etiology, predominantly affecting populations along the historical Silk Road, including the Mediterranean region, the Middle East, and East Asia. Despite decades of investigation, Behçet disease remains diagnostically challenging due to its heterogeneous presentation and fluctuating course. Modern reviews attempt to unify genetic predisposition, immune dysregulation, environmental triggers, and clinical phenotypes into a cohesive framework. The reviewed article aims to provide a comprehensive overview of Behçet disease by synthesizing current evidence on pathogenesis, clinical manifestations, and therapeutic advances.

Scope of the Original Article

The reviewed article broadly addresses four major domains:

1.     Etiopathogenesis of Behçet disease

2.     Genetic susceptibility and immunological mechanisms

3.     Clinical spectrum and organ-specific manifestations

4.     Conventional and emerging therapeutic strategies

This wide scope is appropriate for a narrative review; however, the breadth occasionally limits depth, particularly in areas of clinical management and outcome-based evidence.

Methodological Evaluation (Based on PMC Review Guidelines)

1. Absence of Explicit methodology

The article does not specify:

· Databases searched

· Search terms or keywords

· Inclusion or exclusion criteria

· Time frame of the literature review

Although narrative reviews are not required to follow systematic protocols, the absence of a clearly defined methodology compromises transparency and reproducibility. According to PMC review standards, even brief methodological descriptions significantly enhance scientific rigor.

2.  Evidence Selection and Appraisal

The review incorporates both classical and contemporary studies but demonstrates several limitations:

· Older landmark studies are cited alongside recent trials without justification

· No grading or hierarchy of evidence is provided

· Randomized controlled trials and observational studies are discussed with equal weight This limits the reader’s ability to assess the strength of therapeutic recommendations.

Strengths of the Article

1.  Strong Immunopathogenic Framework

The article excels in describing immune dysregulation, particularly:

· Neutrophil hyperactivity

· Th1 and Th17 cell predominance

· Elevated pro-inflammatory cytokines (TNF-α, IL-6, IL-17)

This mechanistic depth effectively links immunology to clinical disease expression.

2.   Clear Genetic Contextualization

The role of HLA-B51 is thoroughly discussed, including its contribution to disease susceptibility and severity, offering valuable insight into ethnic and geographic variability.

3.  Comprehensive Clinical Overview

The review effectively summarizes major clinical domains:

· Mucocutaneous manifestations

· Ocular involvement (uveitis, retinal vasculitis)

· Neurological and vascular Behçet disease

This structured presentation aids both students and clinicians.

4.  Overview of Biologic Therapies

Biologic agents, particularly TNF-α inhibitors, are clearly explained with reference to their mechanisms of action and expanding clinical indications.

Limitations of the Article

1.  Lack of Methodological Transparency

As noted earlier, failure to describe literature selection weakens scientific credibility and limits reproducibility.

2.  Limited Critical Analysis of Therapeutic Evidence

Although biologic therapies are highlighted, the review does not sufficiently address:

· Trial size and study design

· Long-term safety and relapse rates

· Comparative effectiveness between biologics

As a result, therapeutic optimism is not adequately balanced by critical appraisal.

3.  Inadequate Global Health Perspective

Despite high prevalence in regions with limited resources, the review insufficiently discusses:

· Access to biologic therapies

· Cost-effectiveness

· Variability in diagnostic infrastructure

This omission is significant given the geographic distribution of Behçet disease.

4.  Minimal Focus on Long-Term Outcomes

Disease prognosis, quality of life, and long-term disability—especially in neurological and ocular disease—receive limited attention.

Contribution to the Field

Despite its limitations, the reviewed article contributes meaningfully by:

· Integrating immunology with clinical manifestations

· Highlighting the evolving role of targeted therapy

· Serving as a concise educational resource for trainees

It is particularly valuable as an introductory synthesis rather than a definitive clinical guideline.

Recommendations for Improving Future Reviews

1.     Include a concise methods section outlining search strategy

2.     Introduce evidence-grading tables for therapies

3.     Expand discussion on health-system barriers in endemic regions

4.     Critically appraise biologic therapies, including safety and cost

5.     Incorporate patient-centered outcomes, such as quality of life

Future Research Directions

Key research priorities include:

1.     Identification of reliable biomarkers for disease activity

2.     Long-term safety studies of biologic and targeted therapies

3.     Standardization of disease severity and outcome measures

4.     Cost-effective treatment strategies for low-resource settings

5.     Better understanding of environmental and microbial triggers

Conclusion

The reviewed narrative on Behçet disease provides a well-structured and informative overview of its immunopathogenesis, clinical diversity, and therapeutic evolution. Its principal strengths lie in mechanistic clarity and comprehensive clinical coverage. However, the lack of methodological transparency, limited critical appraisal of treatment evidence, and insufficient global health analysis reduce its overall impact. Future reviews would benefit from greater rigor, balanced evaluation, and attention to real-world implementation challenges. Nevertheless, the article remains a useful resource for clinicians and students seeking foundational understanding of Behçet disease.